DURECT Corporation - Common Stock (DRRX)
Frequently Asked Questions About DURECT Corporation - Common Stock (DRRX)
How does DURECT Corporation engage with investors?
DURECT Corporation actively engages with investors through various channels, including quarterly earnings calls, investor presentations, and participation in industry conferences. The company provides updates on its pipeline, business strategy, and financial performance to keep stakeholders informed about its progress.
How does DURECT Corporation ensure product safety?
DURECT Corporation ensures product safety through rigorous preclinical and clinical testing as mandated by regulatory authorities. The company adheres to industry standards for safety and efficacy, conducting studies that evaluate potential side effects and overall therapeutic profile before seeking regulatory approval.
How does DURECT Corporation leverage technology in its products?
DURECT Corporation utilizes proprietary technologies, such as its drug delivery systems, to enhance the pharmacokinetics and tailor drug release profiles. These technologies are aimed at improving patient compliance and therapeutic efficiency while reducing side effects associated with conventional treatments.
How does DURECT handle intellectual property?
DURECT Corporation prioritizes the protection of its intellectual property through patents and licenses. The company actively manages its patent portfolio to cover its proprietary technologies and therapeutic candidates, ensuring competitive advantage and potential revenue generation through licensing agreements.
How does DURECT stay competitive in the biotech industry?
DURECT Corporation stays competitive by focusing on innovation, strategic partnerships, and a robust pipeline of drug candidates. The company continually invests in research and development while keeping an eye on industry trends and emerging technologies to adapt its strategies and offerings.
Is DURECT Corporation a public company?
Yes, DURECT Corporation is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol DRRX. As a public entity, it is subject to regulatory oversight and provides regular financial updates to its investors.
What are DURECT Corporation’s financial performance indicators?
DURECT Corporation's financial performance indicators include revenue growth, research and development expenditures, operating expenses, and net income or loss. The company monitors these metrics to evaluate its business operations, determine financial health, and strategize future investments.
What are some challenges faced by DURECT Corporation?
Like many biopharmaceutical companies, DURECT Corporation faces challenges such as the high costs and risks associated with drug development, regulatory approval processes, and the need to secure funding for ongoing research. Navigating these challenges requires strategic planning and execution to successfully bring therapies to market.
What are some of the products developed by DURECT Corporation?
DURECT Corporation has developed several innovative products, including DUR-928, an investigational drug for liver disease, and various formulations aimed at pain management. The company’s product pipeline is driven by its unique drug delivery technologies, which enhance the therapeutic experience.
What does DURECT Corporation do?
DURECT Corporation is a biopharmaceutical company focused on the development of innovative drug therapies for patients with chronic pain, liver disease, and other serious conditions. The company leverages its proprietary drug delivery technology to improve the efficacy and safety of its products, aiming to provide solutions that enhance the quality of life for patients.
What is DURECT Corporation's strategy for growth?
DURECT Corporation's strategy for growth involves focusing on its core competencies in drug delivery technology, advancing its therapeutic candidates through clinical development, and exploring strategic partnerships to access additional resources and expertise. The company aims to strengthen its market position by fulfilling unmet medical needs.
What is DURECT's primary focus?
DURECT's primary focus is on the development of drug therapies for pain management and liver disease. The company aims to create long-lasting and effective treatments that minimize side effects and improve patient outcomes.
What is the company’s vision?
DURECT Corporation's vision is to become a leader in the biopharmaceutical industry by developing innovative drug delivery solutions that significantly improve patient outcomes. The company aims to address the needs of patients with serious health conditions while advancing its technologies for wider therapeutic applications.
What is the significance of DUR-928?
DUR-928 is DURECT's lead investigational drug designed for the treatment of liver diseases. It has shown potential in preclinical and clinical trials to protect liver cells and reduce inflammation, making it a promising candidate for patients suffering from acute and chronic liver conditions.
What partnerships or collaborations has DURECT formed?
DURECT Corporation has established collaborations with various pharmaceutical companies and research institutions to advance its drug development programs. These partnerships often focus on collaborative research, clinical trials, and licensing agreements to bring innovative therapies to market effectively.
What recent milestones has DURECT achieved?
In recent years, DURECT Corporation has achieved several milestones, including advancing its product candidates through clinical trials, entering strategic partnerships, and enhancing its technology platforms. These achievements underscore the company's commitment to innovation and its capabilities in developing effective therapeutics.
When was DURECT Corporation founded?
DURECT Corporation was founded in 1998. Since its inception, the company has been dedicated to pioneering drug delivery systems and therapeutic innovations, establishing itself in the biopharmaceutical sector with significant research and development efforts.
Where is DURECT Corporation located?
DURECT Corporation is headquartered in Cupertino, California. This location is strategically chosen to be near Silicon Valley, which fosters innovation and collaboration in the tech and biopharmaceutical industries.
Who are the key executives at DURECT Corporation?
DURECT Corporation is led by a team of experienced professionals in the biotechnology field. Key executives include President and CEO Dr. James E. Brown, who brings extensive industry knowledge and leadership experience, along with other members who contribute to various aspects of business development, research, and operations.
What is the current price of DURECT Corporation - Common Stock?
The current price of DURECT Corporation - Common Stock is 0.7975
When was DURECT Corporation - Common Stock last traded?
The last trade of DURECT Corporation - Common Stock was at 2:50 pm EDT on April 4th, 2025
What is the market capitalization of DURECT Corporation - Common Stock?
The market capitalization of DURECT Corporation - Common Stock is 19.53M
How many shares of DURECT Corporation - Common Stock are outstanding?
DURECT Corporation - Common Stock has 24.49M shares outstanding.